Published On: Mon, Jul 12th, 2021
World | By

Italian COVID-19 Vaccine Shows Strong Immune Response in Mid-Stage Trialon July 12, 2021 at 3:22 pm Save 10% on Citrus trees with code CITRUS
Share This

MILAN—Italy’s hopes of producing its own COVID-19 vaccine were given a boost on Monday when local biotech firm ReiThera said its vaccine candidate showed a strong immune response and no major side effects in intermediate Phase II clinical trials. The vaccine, called GRAd-COV2, induced an antibody response against the SARS-CoV-2 spike protein in over 93 percent of volunteers three weeks after the first dose, reaching 99 percent after the second dose, the company said in a statement. However, ReiThera needs at least 60 million euros ($71 million) to fund final Phase III trials and was dealt a blow in May when a state audit court rejected a plan to pump public funds into the company. ReiThera said on Monday that two independent advisory boards had recommended advancing GRAd-COV2 into Phase III studies, but did not give an update on funding. The company has held early stage talks about potentially supplying …

About the Author